📖
wiki page

Alpha-Synuclein SAA Kinetics Study — Biological Staging Backbone for PD Progression

📖 Wiki Page
experiment641 wordssynced 2026-04-02

Alpha-Synuclein SAA Kinetics Study

Overview

flowchart TD PD["PD"] -->|"causes"| NEURODEGENERATION["NEURODEGENERATION"] PD["PD"] -->|"causes"| DOPAMINERGIC_NEURONS["DOPAMINERGIC_NEURONS"] PD["PD"] -->|"contributes to"| synucleinopathies["synucleinopathies"] PD["PD"] -->|"associated with"| DEPRESSION["DEPRESSION"] PD["PD"] -->|"associated with"| T2DM["T2DM"] TNF["TNF"] -->|"associated with"| PD["PD"] PINK1["PINK1"] -->|"associated with"| PD["PD"] PARKIN["PARKIN"] -->|"associated with"| PD["PD"] NLRP3["NLRP3"] -->|"associated with"| PD["PD"] NRF2["NRF2"] -->|"protects against"| PD["PD"] NEUROINFLAMMATION["NEUROINFLAMMATION"] -->|"contributes to"| PD["PD"] TP53["TP53"] -->|"regulates"| PD["PD"] SNCA["SNCA"] -->|"causes"| PD["PD"] LRRK2["LRRK2"] -->|"causes"| PD["PD"] style PD fill:#4fc3f7,stroke:#333,color:#000

This experiment addresses the #1 ranked PD knowledge gap: "Do alpha-syn seed kinetics define biologically distinct progression trajectories?" (33 points). This study aims to move from symptom-defined PD to biology-forward staging based on neuronal alpha-synuclein status and assay kinetics.

Key Question

How do alpha-synuclein seed amplification assay (SAA) kinetic parameters map to:

  • Progression speed (rapid vs slow)
  • Clinical phenotype (tremor-dominant vs PIGD vs cortical)
  • Treatment response (dopaminergic, GLP-1, disease-modifying)

    • Study Design

    Multi-Cohort Study


    Pool data from 5 prospective PD cohorts with baseline SAA:

    ...
    📖 View canonical wiki page →
    Related Entities
    experiments-alpha-syn-saa-kinetics-pd
    View on SciDEX ↗